Switch theme
Sign up to access all valuation multiples
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.
1997
n/a
LTM Revenue $10.3M
LTM EBITDA -$3.1M
$69.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curatis Holding has a last 12-month revenue (LTM) of $10.3M and a last 12-month EBITDA of -$3.1M.
In the most recent fiscal year, Curatis Holding achieved revenue of n/a and an EBITDA of -$60.3M.
Curatis Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Curatis Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.1M | XXX | -$60.3M | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$3.1M | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$3.8M | XXX | -$59.3M | XXX | XXX | XXX |
| Net Margin | -37% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Curatis Holding's stock price is CHF 12 (or $14).
Curatis Holding has current market cap of CHF 57.6M (or $69.2M), and EV of CHF 57.8M (or $69.4M).
See Curatis Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $69.4M | $69.2M | XXX | XXX | XXX | XXX | $-1.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Curatis Holding has market cap of $69.2M and EV of $69.4M.
Curatis Holding's trades at n/a EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate Curatis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curatis Holding has a P/E ratio of -18.2x.
See valuation multiples for Curatis Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $69.2M | XXX | $69.2M | XXX | XXX | XXX |
| EV (current) | $69.4M | XXX | $69.4M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -22.3x | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | -22.3x | XXX | -16.3x | XXX | XXX | XXX |
| EV/Gross Profit | 29.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -18.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | -40.9x | XXX | -30.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCuratis Holding's last 12 month revenue growth is 148%
Curatis Holding's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Curatis Holding's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Curatis Holding's rule of X is 341% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Curatis Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 148% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -375% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 341% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curatis Holding acquired XXX companies to date.
Last acquisition by Curatis Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Curatis Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Curatis Holding founded? | Curatis Holding was founded in 1997. |
| Where is Curatis Holding headquartered? | Curatis Holding is headquartered in Switzerland. |
| Is Curatis Holding publicy listed? | Yes, Curatis Holding is a public company listed on SWX. |
| What is the stock symbol of Curatis Holding? | Curatis Holding trades under CURN ticker. |
| When did Curatis Holding go public? | Curatis Holding went public in 2022. |
| Who are competitors of Curatis Holding? | Similar companies to Curatis Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Curatis Holding? | Curatis Holding's current market cap is $69.2M |
| What is the current revenue of Curatis Holding? | Curatis Holding's last 12 months revenue is $10.3M. |
| What is the current revenue growth of Curatis Holding? | Curatis Holding revenue growth (NTM/LTM) is 148%. |
| What is the current EV/Revenue multiple of Curatis Holding? | Current revenue multiple of Curatis Holding is 6.7x. |
| Is Curatis Holding profitable? | Yes, Curatis Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Curatis Holding? | Curatis Holding's last 12 months EBITDA is -$3.1M. |
| What is Curatis Holding's EBITDA margin? | Curatis Holding's last 12 months EBITDA margin is -30%. |
| What is the current EV/EBITDA multiple of Curatis Holding? | Current EBITDA multiple of Curatis Holding is -22.3x. |
| What is the current FCF of Curatis Holding? | Curatis Holding's last 12 months FCF is -$1.7M. |
| What is Curatis Holding's FCF margin? | Curatis Holding's last 12 months FCF margin is -16%. |
| What is the current EV/FCF multiple of Curatis Holding? | Current FCF multiple of Curatis Holding is -40.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
